Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment (clinicaltrials.gov) - Jul 15, 2022 - P1 | N=40 | Not yet recruiting | Sponsor: Plus Therapeutics
New P1 trial • Brain Cancer • Glioma • Oncology • Solid Tumor
|